The best and worst of times in therapy development for myasthenia gravis
Author:
Affiliation:
1. Department of Neurology University of Miami Miami Florida
2. Department of Biostatistics University of Alabama at Birmingham Birmingham Alabama
3. Department of Neurology & Rehabilitation Medicine George Washington University Washington DC
Funder
Myasthenia Gravis Foundation of America
Publisher
Wiley
Subject
Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27742
Reference22 articles.
1. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
2. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
3. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis
4. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals
5. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. How should newer therapeutic agents be incorporated into the treatment of patients with myasthenia gravis?;Muscle & Nerve;2024-02-03
2. Measuring treatment adverse event burden in myasthenia gravis: Single‐center prospective evaluation utilizing the Adverse Event Unit (AEU);Muscle & Nerve;2023-09-07
3. Conventional and emerging treatments and controversies in myasthenia gravis;Expert Review of Neurotherapeutics;2023-05-03
4. A Digital Telehealth System to Compute Myasthenia Gravis Core Examination Metrics: Exploratory Cohort Study;JMIR Neurotechnology;2023-04-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3